3rd AnnualInvitation Only
Lymphoma Microenvironment & Immune Therapies
USMeeting 2027
NO LyMIT · Two days, one room.
October 2027 (dates TBC)
New Orleans, LA
Dates
October 2027
Dates TBC
Venue
New Orleans, LA
Venue TBC
Audience
By invitation
KOLs & fellows TBC
Format
To be announced
Program details to follow
A Curated Room: The People Shaping Practice
This third annual, invitation-only meeting convenes a deliberately small faculty of leading lymphoma biology and immunotherapy KOLs alongside hand-selected fellows and junior faculty, the clinicians and scientists defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The full agenda and faculty will be announced soon. Every session will pair expert talks with a moderated panel, sustained, close-quarters engagement rather than a lecture hall.
Meeting Co-Chairs
Listed alphabetically by surname
Christopher Flowers
MD Anderson Cancer Center, Houston, TX
Michael Green
MD Anderson Cancer Center, Houston, TX
Faculty Drawn From
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
Talks across 8 sessions, each paired with a panel and a case
NO LyMIT US Meeting 2027
Proposed Faculty
Faculty to be announced
Ohio State University, Columbus, OH
Atrium Health Levine Cancer Institute, Charlotte, NC
Sutter Health/Palo Alto Medical Foundation, San Francisco, CA
UCLA David Geffen School of Medicine, Los Angeles, CA
University of Colorado Anschutz, Aurora, CO
Ohio State University, Columbus, OH
UC San Diego, La Jolla, CA
MD Anderson Cancer Center, Houston, TX
Memorial Sloan Kettering, New York, NY
Yale Cancer Center, New Haven, CT
UC San Diego, La Jolla, CA
Florida Cancer Specialists, West Palm Beach, FL
Fred & Pamela Buffett Cancer Center, Omaha, NE
Ohio State University, Columbus, OH
Dana-Farber Cancer Institute, Boston, MA
NYU Langone Health, New York, NY
Cedars-Sinai, Los Angeles, CA
UCLA, Los Angeles, CA
Mount Sinai Medical Center, Miami Beach, FL
Dana-Farber Cancer Institute, Boston, MA
UC Irvine, Orange, CA
MD Anderson Cancer Center, Houston, TX
MD Anderson Cancer Center, Houston, TX
Massachusetts General Hospital, Boston, MA
Coming Soon
Proposed Agenda
15 min
5 min
30 min
20 min
65 min
October 2027
Ohio State University, Columbus, OH
Agenda & Faculty to be Announced
ModeratorTBC
Endometrial Molecular Classification
Casey CosgroveOhio State University, Columbus, OH
Multiplex Biomarker Workflow for Ovarian Cancer
Barrett LawsonMD Anderson Cancer Center, Houston, TX
HRD/BRCA Testing: Assays, Spatial Heterogeneity & Front-Line PARPi Access (± RNA/fusions)
Dana ChaseUCLA David Geffen School of Medicine, Los Angeles, CA
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
Adjuvant Therapy for dMMR (NRG-GY020 Readout)
Floor BackesOhio State University, Columbus, OH
Chemo/ICI in Advanced Recurrent Disease + Mechanisms of Resistance
Ramez EskanderUC San Diego, La Jolla, CA
ICI Instead of Chemo in dMMR
Brian SlomovitzMount Sinai Medical Center, Miami Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
Adjuvant Therapy for pMMR by Molecular Subgroup (RAINBO, PORTEC-4)
Brad CorrUniversity of Colorado Anschutz, Aurora, CO
Non-dMMR Advanced Recurrent 1L & Optimal Maintenance
Kathleen MooreFred & Pamela Buffett Cancer Center, Omaha, NE
2L+ Endometrial Cancer ADCs & Small Molecules
Bhavana PothuriNYU Langone Health, New York, NY
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
What ADCs Are: Beyond Target, Payload & Linker
Paolo TarantinoDana-Farber Cancer Institute, Boston, MA
Toxicities & Need for MDT: ILD, OM, Ocular
BJ RimelCedars-Sinai, Los Angeles, CA
Dose & Regimen Optimization, Including Duration
Bradley MonkFlorida Cancer Specialists, West Palm Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
Day Two · Saturday, April 24, 2027
Session VOvarian Cancer: Front Line Considerations
ModeratorTBC
HRD+ Use of PARP Inhibitors
Ying LiuMemorial Sloan Kettering, New York, NY
HRD Test Negative: Bev vs No Bev; Trials to Watch
David O’MalleyOhio State University, Columbus, OH
Low-Grade Ovarian Cancer
Jubilee BrownAtrium Health Levine Cancer Institute, Charlotte, NC
Young Investigator Case Presentation
TBD
Panel Discussion
Coffee Break
Session VIOvarian Cancer: Recurrent
ModeratorTBC
Beyond PARP: The Replication-Stress Axis (ATR/WEE1/PKMYT1/CCNE1)
Timothy YapMD Anderson Cancer Center, Houston, TX
ADCs in PSOC and PROC: Mechanisms of Resistance
Rebecca PorterDana-Farber Cancer Institute, Boston, MA
Other Modalities in PROC: Working Up & Sequencing Options
John ChanSutter Health/Palo Alto Medical Foundation, San Francisco, CA
Young Investigator Case Presentation
TBD
Panel Discussion
Lunch Break + Faculty and Fellow Photo
Session VIICervical Cancer
ModeratorTBC
Local Regional Treatment, ICI & Unanswered Questions
Jyoti MayadevUC San Diego, La Jolla, CA
1st-Line Metastatic & Opportunities to Improve
Krishnansu TewariUC Irvine, Orange, CA
2L ADCs: Finally Something That Works
Ritu SalaniUCLA, Los Angeles, CA
Young Investigator Case Presentation
TBD
Panel Discussion
Coffee Break
Session VIIINew Modalities
ModeratorTBC
TCEs & Bispecifics
Oladapo YekuMassachusetts General Hospital, Boston, MA
Novel Small Molecules: KIF18A and Others
Shannon WestinMD Anderson Cancer Center, Houston, TX
ADCs with Multiple Targets and/or Multiple Payloads: Hope versus Hype
Patricia LoRussoYale Cancer Center, New Haven, CT
Young Investigator Case Presentation
TBD
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
